Genetic and preclinical evidence implicating chondroitin sulfate as a matritherapeutic target for the treatment of type 2 diabetes

Abstract excerpt

Peptide-based treatments for type 2 diabetes (T2D) are often limited by variable patient responses, frequent discontinuation, and substantial costs. Emerging lines of evidence link the extracellular matrix (ECM) to the pathophysiology of T2D, highlighting a largely unexplored modality for managing this heterogenous disease. Chondroitin sulfate (CS), a major glycosaminoglycan in the ECM, has been suggested to impro...

Topics

Open a Topic to create a Post that cites this publication.

• Blood Glucose
• Cardiovascular Function and Risk Factors
• Diabetes Mellitus, Experimental
• Diet and metabolism studies
• Hyperglycemia
• Hyperinsulinism
• Metabolism, Diabetes, and Cancer
• Musculoskeletal pain and rehabilitation

Identifiers and source

Literature Corpus work

0a521f67-171e-517c-af3a-46825367e220

DOI

10.1101/2025.11.12.688143